Le Lézard
Classified in: Ebola virus, Health, Covid-19 virus
Subject: MRR

Human combination vaccines market size to increase by USD 6,046.98 million; North America to account for 45% of market growth - Technavio


NEW YORK, Jan. 24, 2023 /PRNewswire/ -- The Human Combination Vaccines Market by Type, Channel, and Geography - Forecast and Analysis 2023-2027 report has been published by Technavio. Market size is forecast to grow by USD 6,046.98 million between 2022 and 2027 at a CAGR of 8.13%. The report provides a comprehensive analysis of growth opportunities at regional levels, new product launches, the latest trends, and the post-pandemic recovery of the global market. Download A PDF Sample Report

Regional Analysis

By region, the global human combination vaccines market is segmented into North America, Europe, Asia, and Rest of World (ROW). North America will account for 45% of market growth during the forecast period. Factors such as the continuous efforts by vendors and national organizations to promote the use of human combination vaccines and strict regulatory norms that recommend the proper vaccination of infants are driving the growth of the human combination vaccines market in North America. Buy the report

Company Profiles

The human combination vaccines market report includes information on the key products and recent developments of leading vendors, including:

Market Dynamics

The market is driven by factors such as increasing antiviral drug resistance, increase in pediatric population, and rise in cases of infectious diseases. However, the incompatibility of vaccine components is hindering the market growth.

Competitive Analysis

The competitive scenario categorizes companies based on various performance indicators. Some of the factors considered include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, and growth in market share among others. Request a Sample

Market Segmentation

Related Reports:

Technavio's library includes over 17,000+ reports, covering more than 2,000 emerging technologies. Subscribe to our "Basic Plan" at just USD 5,000 and get lifetime access to Technavio Insights

What are the key data covered in this human combination vaccines market report?

Human Combination Vaccines Market Scope

Report Coverage

Details

Page number

168

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 8.13%

Market growth 2023-2027

USD 6046.98 million

Market structure

Concentrated

YoY growth 2022-2023 (%)

7.45

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 45%

Key countries

US, Canada, UK, Germany, and Japan

Competitive landscape

Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks

Key companies profiled

Abbott Laboratories, Arabio, Bharat Biotech Ltd., Biological E. Ltd., Cadila Healthcare Ltd., CSL Ltd., Daiichi Sankyo Co. Ltd., GlaxoSmithKline Plc, Grifols SA, LG Corp., Meiji Holdings Co. Ltd., Merck and Co. Inc., Mitsubishi Chemical Holdings Corp., Panacea Biotec Ltd., Pfizer Inc., PT Bio Farma, Sanofi SA, Serum Institute of India Pvt. Ltd., Takeda Pharmaceutical Co. Ltd., and Walvax Biotechnology Co. Ltd.

Market dynamics

Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Table of contents:

1 Executive Summary

2 Market Landscape

3 Market Sizing

4 Historic Market Size

5 Five Forces Analysis

6 Market Segmentation by Type

7 Market Segmentation by Channel

8 Customer Landscape

9 Geographic Landscape

10 Drivers, Challenges, and Trends

11 Vendor Landscape

12 Vendor Analysis

13 Appendix

About Us 
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact 
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio


These press releases may also interest you

at 18:47
As the world eagerly anticipates advancements in diagnostics, Biolabs International LLC stands at the forefront of innovation with the announcement of an exclusive distribution agreement. In response to the unprecedented demand for the highly...

at 18:15
Market Cap : US$3,975.7 million*Note: For the figures included in the FFSS, the Company has accounted for the effects of inflation adjustment adopted by Resolution 777/18 of the Comisión Nacional de Valores ("CNV"), which establishes...

at 17:20
Swiss Water Decaffeinated Coffee Inc. ("Swiss Water" or "the Company"), a leading specialty coffee company and premium green coffee decaffeinator, today reported financial results for the three months ended March 31, 2024....

at 17:05
Sangoma Technologies Corporation ("Sangoma" or the "Company"), a trusted leader in delivering cloud-based Communications as a Service solutions for companies of all sizes, today announced its third quarter financial results and unaudited condensed...

at 17:01
Manulife Financial Corporation ("Manulife" or the "Company") reported its first quarter results for the period ended March 31, 2024, delivering strong core ROE and topline growth, and closing the largest long-term care ("LTC") reinsurance transaction...

at 17:00
BSR Real Estate Investment Trust ("BSR", or the "REIT") today announced its financial results for the three months ended March 31, 2024 ("Q1 2024"). All comparisons are to the corresponding periods in the prior year. Results are presented in U.S....



News published on and distributed by: